fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors – Eli Lilly

Written by | 14 Jun 2024

The FDA has granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following: i. advanced or… read more.

Zepbound (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks – Eli Lilly

Written by | 16 Dec 2023

Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.

Mounjaro versus Wegovy in treatment of Obesity – Eli Lilly

Written by | 9 Dec 2023

Overweight or obese adults lost more weight and shed pounds faster using Mounjaro than those taking Novo Nordisk’s rival weight loss drug (Wegovy/Ozempic)) according to an analysis of… read more.

Jaypirca (pirtobrutinib) has accelerated approval from the FDA for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy – Eli Lilly

Written by | 8 Dec 2023

Eli Lilly and Company announced that the FDA approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with chronic lymphocytic leukemia or… read more.

CHMP positive for Mounjaro (tirzepatide) for the treatment of obesity – Eli Lilly

Written by | 16 Nov 2023

Eli Lilly’s Mounjaro is recommended for use in Europe for the treatment of obesity. The recommendation comes the same week the drug was approved for obesity treatment in… read more.

FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors – Eli Lilly

Written by | 11 Nov 2023

The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.

FDA approves Omvoh (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis – Eli Lilly

Written by | 1 Nov 2023

Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment… read more.

Landmark 5-year monarchE outcome data demonstrate Verzenio (abemaciclib)’s long-term impact on cancer recurrence in high-risk early breast cancer – Eli Lilly

Written by | 29 Oct 2023

Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.

FDA approves Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease – Boehringer + Eli Lilly

Written by | 28 Sep 2023

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular… read more.

Jardiance approved in the EU for the treatment of adults with chronic kidney disease – Boehringer + Eli Lilly

Written by | 5 Aug 2023

The European Commission (EC) approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company have announced. The approval… read more.

FDA approves Jardiance for the treatment of type 2 diabetes in children 10 years and older – Boehringer Ingelheim + Eli Lilly

Written by | 27 Jun 2023

The FDA has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with… read more.

First-of-its-kind head-to-head clinical trial reaffirms the efficacy of Emgality in episodic migraine prevention – Eli Lilly

Written by | 20 Jun 2023

Eli Lilly and Company announced results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet), the first and only trial of its… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.